Baird Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
October 8, 2024 9:17 AM EDTStifel analyst Dae Gon ha reiterated a Buy rating and $74.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).
The analyst commented: "At face, today's FDA update on diazoxide choline-controlled release (DCCR) for Prader-Willi syndrome (PWS) comes as a... More
Oppenheimer Reiterates Outperform Rating on Soleno Therapeutics Inc. (SLNO)
October 8, 2024 9:14 AM EDTOppenheimer analyst Leland Gershell reiterated an Outperform rating and $65.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).
The analyst commented: "This morning, Soleno announced that the FDA does not see a need to hold an advisory committee meeting to discuss DCCR ahead... More
Soleno Therapeutics (SLNO) Announces Regulatory Update on DCCR Extended-Release Tablets to Treat Prader-Willi Syndrome
October 8, 2024 8:31 AM EDTSoleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA).
The FDA Review Division has determined that... More
